急性非复杂性B型主动脉夹层与壁内血肿早期主动脉重塑的预后意义
该多中心回顾性研究纳入136例初始无并发症并接受最佳药物治疗的急性B型主动脉夹层(92例)或壁内血肿(44例)患者,评估其自然病程与早期主动脉重塑的预后价值。结果显示B型夹层5年无事件生存率62.6%,壁内血肿68.9%;夹层患者发病后6个月内主动脉增长5 mm与不良事件风险增加相关(相对风险2.29)。
要点
- 初始无并发症的B型主动脉夹层患者5年内超过三分之一发生不良事件。
- B型夹层发病后6个月内主动脉直径增长5 mm与不良事件风险增加相关(RR 2.29)。
- 约60%壁内血肿在12个月内吸收,未吸收者不良事件风险第一年最高。
核心结论
- 初始无并发症的B型主动脉夹层患者在最佳药物治疗下5年内超过三分之一发生不良事件。
- B型夹层早期主动脉增长与不良事件风险增加相关。
- 未吸收的壁内血肿不良事件多发生在发病后第一年。
研究设计与样本
- 回顾性多中心队列研究,纳入欧洲与美国2个主动脉中心共136例患者(B型夹层92例,壁内血肿44例)。
- 患者均为初始住院期间无并发症并接受最佳药物治疗。
- 均有发病时(≤14天)及随访期间的CT血管造影扫描。
主要发现
- B型夹层1年、2年、5年无事件生存率分别为84.3%(95%CI 74.4-90.6)、75.4%(95%CI 64.0-83.7)、62.6%(95%CI 68.9-73.6)。
- 壁内血肿1年、2年、5年无事件生存率分别为76.5%(95%CI 57.8-87.8)、76.5%(95%CI 57.8-87.8)、68.9%(95%CI 45.2-83.9)。
- B型夹层患者发病后6个月内主动脉直径增长5 mm与不良事件相对风险2.29(95%CI 1.70-3.09)相关,中位6个月增长为2.4 mm。
- 约60%壁内血肿在12个月内吸收,未吸收者不良事件风险在发病后第一年最高,之后保持稳定。
临床怎么用
- 对初始无并发症的B型夹层患者,应密切监测发病后6个月内的主动脉直径变化以评估不良事件风险。
- 壁内血肿患者若12个月内未吸收,应加强第一年的随访监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with Stanford type B aortic dissections (ADs) are at risk of long-term disease progression and late complications. The aim of this study was to evaluate the natural course and evolution of acute type B AD and intramural hematomas (IMHs) in patients who presented without complications during their initial hospital admission and who were treated with optimal medical management (MM). METHODS: Databases from 2 aortic centers in Europe and the United States were used to identify 136 patients with acute type B AD (n = 92) and acute type B IMH (n = 44) who presented without complications during their index admission and were treated with MM. Computed tomography angiography scans were available at onset (≤14 days) and during follow-up for those patients. Relevant data, including evidence of adverse events during follow-up (AE; defined according to current guidelines), were retrieved from medical records and by reviewing computed tomography scan images. Aortic diameters were measured with dedicated 3-dimensional software. RESULTS: The 1-, 2-, and 5-year event-free survival rates of patients with type B AD were 84.3% (95% confidence interval [CI], 74.4-90.6), 75.4% (95% CI, 64.0-83.7), and 62.6% (95% CI, 68.9-73.6), respectively. Corresponding estimates for IMH were 76.5% (95% CI, 57.8-87.8), 76.5% (95% CI, 57.8-87.8), and 68.9% (95% CI, 45.2-83.9), respectively. In patients with type B AD, risk of an AE increased with aortic growth within the first 6 months after onset. A diameter increase of 5 mm in the first half year was associated with a relative risk for AE of 2.29 (95% CI, 1.70-3.09) compared with the median 6 months' growth of 2.4 mm. In approximately 60% of patients with IMH, the abnormality resolved within 12 months and in the patients with nonresolving IMH, risk of an adverse event was greatest in the first year after onset and remained stable thereafter. CONCLUSIONS: More than one third of patients with initially uncomplicated type B AD suffer an AE under MM within 5 years of initial diagnosis. In patients with nonresolving IMH, most adverse events are observed in the first year after onset. In patients with type B AD an early aortic growth is associated with a greater risk of AE.
引用
- Sailer AM, Nelemans PJ, Hastie TJ, et al. Prognostic significance of early aortic remodeling in acute uncomplicated type B aortic dissection and intramural hematoma. J Thorac Cardiovasc Surg. 2017. PMID: 28668458. doi:10.1016/j.jtcvs.2017.04.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。